Please ensure Javascript is enabled for purposes of website accessibility

Why Adamas Pharmaceuticals Inc. Jumped Higher Today

By Brian Orelli, PhD - Oct 30, 2017 at 6:57PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Steven Cohen's Point72 Asset Management disclosed a big stake in the biotech, but be careful following the guru.

What happened

Adamas Pharmaceuticals (ADMS) closed up 21% on Monday, after Point72 Asset Management disclosed in an SEC document on Friday after the bell that it boosted its stake in the drugmaker.

So what

The fund now owns 1,144,000 shares of Adamas, and Point72's associated fund, Cubist Systematic Strategies, owns another 1,200, giving Steven Cohen, who runs the management company, a 5.1% control of the Adamas' shares.

It's understandable that investors would want to follow Cohen's trades, considering his smart investments have generally outpaced his not-so-smart ones. But the problem with following a guru based on SEC documents is that investors can't tell when the purchase was made or at what price. It's possible that Point72 bought a majority of the shares before the FDA approved Adamas' Parkinson's disease drug Gocovri in August, and the fund is just waiting to take its profits with no plans to become a long-term shareholder. Ironically, for all we know, today's jump in the stock price because Point72 disclosed that it owns shares could be what pushes Point72 to lighten its stake or sell out altogether. And we wouldn't know that until the group files another SEC document disclosing that it doesn't own shares.

A dictionary open to the definition of Parkinson's disease

Image source: Getty Images.

Now what

While Point72's news is causing short-term movement of the share price, the long-term price will be determined by the sales of Gocovri.

Investors will get an update on the launch of Gocovri when Adamas Pharmaceuticals releases third-quarter earnings on Thursday. When Gocovri was approved, Adamas said it planned to launch the drug in the fourth quarter and deploy a full sales force in January 2018. The company has already set up a patient-support program called Gocovri Onboard that is collecting information from potential patients and prescribers, which will hopefully help the company hit the ground running when the drug becomes available.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Adamas Pharmaceuticals, Inc. Stock Quote
Adamas Pharmaceuticals, Inc.
ADMS

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
394%
 
S&P 500 Returns
127%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.